Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Ovarian news from ESMO 2018: SOLO-1 results for olaparib

Ovarian cancer research is moving forwards, as displayed at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Kathleen Moore, MD, MS, of the Stephenson Cancer Center, Oklahoma City, OK, gave an update on the SOLO-1 trial (NCT01844986) of olaparib maintenance monotherapy for BRCA-mutated ovarian cancer after first-line platinum-based chemotherapy.